reference/7530361

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7530361

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, Non-P.H.S.
endingPage	1389
issn	0270-4137 1097-0045
issueIdentifier	16
pageRange	1382-1389
publicationName	The Prostate
startingPage	1382
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_af01e20ea819a4f2bb16159c7868869a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c2aa3126a4b0602d62386f7e3fc549c0 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b16c81df06fdae7b7e931de82a4ab23e http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7774097ef01ba287de16cd9f6cab7e1f http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_01a74961205fd42863434f526764c2b4 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d62f51386142d8e7576b9b70134d6e59 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_87a2b4ff6a0e8dbdfb94cb42266b1332
bibliographicCitation	Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. The Prostate. 2021 Sep 13;81(16):1382–9. doi: 10.1002/pros.24236.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5510-0661 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2139-7951 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8777-7343 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8e7d588c38d1af755f947dd965a5128 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_564f5b65e03b6143ce2f1564b7da6192 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2245222351e6a0f94aafd592ad3a0de2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d1cbf23fce32863f5534d7190f6a3ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7592-6567 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d75400a670a87ba365425c1ebe61f8f3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c98d5d3a05083d20af538d7ea2f0f70 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0821-6503 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_422f7ecc7d58fa8d1f145be71e425365 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3691-6454 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_50ef4fd3e70c337dd3824d951527937c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1230-3255 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3658-1858 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2bbc741e3896d2c77224eb960e472ff8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d08bf03834d16555394b5f04e90c569f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1365-0702 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d32891b6e3de99fab2a45e57a7f512e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_96988e0b6d45d8af784555eee7593a72 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0031-9655
date	2021-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/pros.24236 https://pubmed.ncbi.nlm.nih.gov/PMC8563438 https://pubmed.ncbi.nlm.nih.gov/34516663
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6523 https://portal.issn.org/resource/ISSN/0270-4137 https://portal.issn.org/resource/ISSN/1097-0045
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
discusses	http://id.nlm.nih.gov/mesh/M0237229 http://id.nlm.nih.gov/mesh/M0001114 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0026444 http://id.nlm.nih.gov/mesh/M000601132 http://id.nlm.nih.gov/mesh/M0242709 http://id.nlm.nih.gov/mesh/M0577955 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0481741 http://id.nlm.nih.gov/mesh/M0248389 http://id.nlm.nih.gov/mesh/M0549409 http://id.nlm.nih.gov/mesh/M0002327 http://id.nlm.nih.gov/mesh/M0016576 http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010669Q000627 http://id.nlm.nih.gov/mesh/D000067856Q000627 http://id.nlm.nih.gov/mesh/D064129Q000473 http://id.nlm.nih.gov/mesh/D064129Q000235 http://id.nlm.nih.gov/mesh/D064007Q000235 http://id.nlm.nih.gov/mesh/D000736Q000627 http://id.nlm.nih.gov/mesh/D009570Q000627 http://id.nlm.nih.gov/mesh/D064129Q000401 http://id.nlm.nih.gov/mesh/D064129Q000628 http://id.nlm.nih.gov/mesh/D001549Q000627 http://id.nlm.nih.gov/mesh/D024682Q000235 http://id.nlm.nih.gov/mesh/D054539Q000592 http://id.nlm.nih.gov/mesh/D000077143Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D018579 http://id.nlm.nih.gov/mesh/D018095 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D017430Q000097 http://id.nlm.nih.gov/mesh/D060787 http://id.nlm.nih.gov/mesh/D012189 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D009367
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID130443213 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_533622b82f51bc5431a771c088f3bdd9 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6f3ef4a5ab86c1588ba1fc89f4c730bb http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132971 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529

Total number of triples: 97.